• ASP Isotopes posted revenue of $4.18 million for the quarter ended March 31, 2026, up 279.31% year over year, as it added LNG sales from the Renergen acquisition alongside higher radiopharmacy volume.
• Loss before income tax widened to $26.74 million from $8.53 million a year earlier, as operating expenses climbed to $26.55 million from $8.28 million.
• Research and development expense rose to $5.26 million from $1.53 million, while selling, general and administrative costs increased to $21.29 million from $6.75 million.
• Cash and cash equivalents totaled $207.3 million at March 31, 2026, with short-term investments of $83.2 million.
• The company is targeting initial commercial shipments of enriched Si-28 around mid-year 2026, with enriched C-14 and Yb-176 shipments targeted in the third quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ASP Isotopes Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-232658), on May 20, 2026, and is solely responsible for the information contained therein.